Drug Trial Radar · NCT07709715
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Dec 2028
Study completion Dec 2032
Sponsor
- Lead sponsor
- Nexcella Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Immix Biopharma, Inc.
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Conditions
- Light Chain (AL) Amyloidosis
Interventions
NXC-201Biological
NXC-201 CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding a proprietary chimeric antigen receptor (CAR) targeted to human BCMA.
Dara-CyBorDDrug
Daratumumab plus CyBorD combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall complete hematologic response (CHR) rate using consensus recommendations for AL amyloidosis treatment response criteria per protocolTime frame: 24 months
- Major Organ Deterioration Progression-Free Survival (MOD-PFS)Time frame: 60 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.